Press release
Aiming for tighter surveillance of excipients used in medicines
Baltimore (USA), Münster (DE), 06 May 2013. The EXCiPACT certification scheme, an initiative of industrial associations from excipient and pharma suppliers, has officially been launched in the US. EXCiPACT is aiming for an independent and impartial monitoring of Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) compliance. The manufacturing and distribution operations of excipient suppliers will be subject to regular on-site monitoring by auditors from accredited Certification Bodies. A few weeks ago, EXCiPACT has accredited mdc medical device certification GmbH in cooperation with blue inspection body GmbH (www.blue-inspection.com) as the first global Certification Body. „We have already conducted several pilot audits in Germany“, states Dr. Stefan Kettelhoit, Managing Director of blue inspection body, at the launch meeting of EXCiPACT during the Expo & Conference ExcipientFest in Baltimore: „The new surveillance system for excipients is operational.“Single Audits to be replaced by certified audit reports
Currently, each finished-dose drug manufacturer coordinates his own on-site audits in order to monitor GMP and GDP compliance of excipients such as Lactose, Cellulose or Glycerole individually. Some manufacturers of excipients face more than 100 audit requests of different customers per year. It is the aim of the EXCiPACT initiative to pool, to improve and to standardize these audits. „The slogan is ‚Less but more professional audits’, EXCiPACT has thus defined particular high standards for every single audit“, explains Dr. Stefan Kettelhoit from blue inspection body GmbH (www.blue-inspection.com): „It is thereby ensured, that these kind of new excipient Third-Party-Audits are also accepted by the health authorities globally.“ Instead of conducting their own audit visits, finished-dose drug manufacturers will be able to refer to these audit reports and the EXCiPACT certificates. For excipient suppliers as well as pharmaceutical manufacturers the participation at the EXCiPACT scheme is on a voluntary basis.
The Expo & Conference ExcipientFest took place from April 29th to May 3rd in Baltimore, Maryland (USA).
The blue inspection body GmbH examines the Good Manufacturing Practices (GMP) of pharmaceutical companies around the globe. Third-party audits by blue efficiently relieve manufacturing authorisation holders, API suppliers and API manufacturers. Blue inspection body GmbH is the first independent and accredited service provider for GMP audits in the European Union.
Contact:
blue inspection body GmbH
Hafenweg 18-20
D-48155 Münster
Contact person:
Dr. Stefan Kettelhoit
Phone: +49 (0)251 - 625620-40
stefan.kettelhoit@blue-inspection.com
www.blue-inspection.com
Agency contact:
co-operate Wegener & Rieke GmbH
Zumsandeplatz 32
D-48145 Münster
Contact person:
Christian Rieke
Tel.: +49 (0)251 - 3222611
wort@co-operate.net
www.co-operate.net
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aiming for tighter surveillance of excipients used in medicines here
News-ID: 259885 • Views: …
More Releases from blue inspection body GmbH
blue inspection body reports on experiences with excipient audits
The industry initiative EXCiPACT was launched a year ago to improve monitoring of pharmaceutical excipients. At the CPhI China in Shanghai and the ExcipientFest Europe in Amsterdam, the auditors of blue inspection body (www.blue-inspection.com) have now drawn an initial conclusion: “Overall, the level of awareness for Good Manufacturing and Good Distribution Practices at excipient manufacturers has increased significantly in the past twelve months,” declared lead auditor Dr. Norbert Waldöfner in…
Manufacturers of Pharma-Excipients aiming for certified monitoring
Muenster, 29 November 2012. Supported by extensive professional knowledge of blue inspection body GmbH, the mdc medical device certification GmbH represents the first European Certification Body for pharmaceutical excipients. mdc and EXCiPACT have signed a respective framework agreement. The EXCiPACT certification scheme is an initiative of industrial associations from excipient and pharma suppliers, aiming for a professional surveillance of Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) compliance. The…
Blue Inspection Body audits Good Manufacturing Practice compliance of Biotec-der …
Muenster (Germany), 16 March 2012. The first accredited Good Manufacturing Practice (GMP) inspection body in Europe broadens its range of services: blue inspection body (www.blue-inspection.com) successfully completed an audit of an antibody manufacturing site for a Russian pharmaceutical company. The contract giver, OOO NPF MATERIA MEDICA HOLDING, uses the Biotech-derived glycoprotein for manufacturing homoeopathic medicinal products supplied to the Russian market.
Pharmaceutical manufacturers must verify compliance with GMP standards along the…
blue inspection body extends the API audit team by Dr Norbert Waldöfner
Muenster (Germany), 22 June 2011. Effective June 1st, Dr Norbert Waldöfner was nominated as a new GMP-Auditor of blue inspection body GmbH (blue-inspection.com). Thus the first accredited European inspection body for active pharmaceutical ingredients (APIs) extends the team of available team to twelve qualified auditors. At the same time the Chemist will takeover the function as quality management representative. On behalf of pharmaceutical companies, blue inspection body GmbH examines the…
More Releases for EXCiPACT
Ocular Drug Excipient Market Overall Study Report 2023-2029 | BASF, Beneo, Evoni …
MarketsandResearch.biz has publicized the addition of a new report entitled Ocular Drug Excipient Market 2023 that has been designed with current and past developments in mind that are critical to utilizing profitable predictive developments to ensure steady market growth. The report aims to provide the most segmented consumption and sales data of different types, downstream consumption fields, and competitive landscapes in different regions and countries around the world. The report…
Biopharmaceutical Excipients Market Size, Share, Statistics, Trends, Competitive …
The global Biopharmaceutical Excipients industry is forecasted to grow with 7.3% CAGR between the year 2022 to 2030 and the biopharmaceutical excipients market is foreseen to reach USD 4.4 Billion by 2030.
Rapid development of the biopharmaceutical business because of expanding manufacturing capacities is one of the key main impetus of this market. Increase in the quantity of protein therapeutics combined with the presence of a considerable number of excipients to…
Ocular Drug Excipient Market 2021: Global Size, Supply-Demand, Product Type and …
Market Summary
A newly published report titled “(Ocular Drug Excipient Market)” by QY Research throws light on the industry dynamics and current and future trends that play a key role in determining the business expansion. The report also highlights the key driving factors and restraints that are impacting the growth. For a comprehensive understanding, the professionals have reviewed the regulatory scenario, market entry strategies, best industry practices, pricing strategy, technology landscape,…
Pharmaceutical Excipients Market Size To Reach USD 10.15 Billion By 2027 – Top …
The rise in the number of diseases globally, the development of new drugs, technological advances for formulations ongoing new product launches, and strategic collaboration, awareness among people for better healthcare facilities are key factors contributing to the high CAGR of the Pharmaceutical Excipients market during the forecast period.
According to the current analysis of Reports and Data, the global Pharmaceutical Excipients Market valued at USD 6.53 billion in 2019 and is…
IQ4I Research & Consultancy published a new report on “Pharmaceutical Excipien …
Pharmaceutical Excipients are non-active substances combined with active pharmaceutical ingredient (API) during formulation to form a desired finished drug product, which helps in modulating solubility, bioavailability, stability and perform a wide range of functions. Pharmaceutical excipients are naturally derived or manufactured through semi-synthetic or synthetic modes. They are classified based on their physio-chemical characteristics in formulating different dosage forms based on nature of active ingredient and intended route of administration.…
blue inspection body reports on experiences with excipient audits
The industry initiative EXCiPACT was launched a year ago to improve monitoring of pharmaceutical excipients. At the CPhI China in Shanghai and the ExcipientFest Europe in Amsterdam, the auditors of blue inspection body (www.blue-inspection.com) have now drawn an initial conclusion: “Overall, the level of awareness for Good Manufacturing and Good Distribution Practices at excipient manufacturers has increased significantly in the past twelve months,” declared lead auditor Dr. Norbert Waldöfner in…
